G1 Therapeutics Inc (NASDAQ:GTHX) Sellers Declined Their Shorts By 10.67% As Of Feb 14, 2019

G1 Therapeutics Inc (NASDAQ:GTHX) reported a decrease of 10.67% in short interest. It was announced in February by FINRA the 1.60 million short interest on GTHX. Previously was reported down change of 10.67% from 1.79 million shares. Previous GTHX’s position will need 6 days to recover. It has 268,500 average volume. G1 Therapeutics Inc’s short interest float is 6.91%.

The stock decreased 1.40% or $0.3 during the last trading session, touching $21.08.G1 Therapeutics, Inc. has volume of 147,032 shares. Since February 14, 2018 GTHX has risen 68.97% and is uptrending. GTHX outperformed by 68.97% the S&P 500.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States.The company has $783.86 million market cap. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage.Last it reported negative earnings.

For more G1 Therapeutics, Inc. (NASDAQ:GTHX) news released briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “G1 Therapeutics Announces Pricing of Offering of Common Stock – GlobeNewswire” released on September 18, 2018, “Analysis: Positioning to Benefit within Skyworks Solutions, Atmos Energy, Ellie Mae, ScanSource, REV Group, and GTx — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” on February 07, 2019, “G1 Therapeutics down 18% on mixed results from mid-stage study of trilaciclib – Seeking Alpha” with a publish date: November 27, 2018, “UBS likes Lilly in premarket analyst action – Seeking Alpha” and the last “Benzinga’s Top Upgrades, Downgrades For February 7, 2019 – Benzinga” with publication date: February 07, 2019.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.